Your browser doesn't support javascript.
loading
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Yofe, Ido; Landsberger, Tomer; Yalin, Adam; Solomon, Isabelle; Costoya, Cristobal; Demane, Dafne Franz; Shah, Mansi; David, Eyal; Borenstein, Chamutal; Barboy, Oren; Matos, Ignacio; Peggs, Karl S; Quezada, Sergio A; Amit, Ido.
Afiliación
  • Yofe I; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Landsberger T; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Yalin A; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Solomon I; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Costoya C; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Demane DF; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Shah M; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • David E; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Borenstein C; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Barboy O; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Matos I; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Peggs KS; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Quezada SA; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.
  • Amit I; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.
Nat Cancer ; 3(11): 1404, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36376510
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Israel